Simultaneous Evaluation of Prepulse Inhibition with EMG and EEG using Advanced Artifact Removal Techniques
Carregando...
Citações na Scopus
Tipo de produção
conferenceObject
Data de publicação
2016
Título da Revista
ISSN da Revista
Título do Volume
Editora
IEEE
Autores
FRAGA, Francisco J.
NOYA, Claudemiro V.
ZIMIANI, Maria I.
AVILA, Milton A.
SHUHAMA, Rosana
DEL-BEN, Cristina M.
MARTIN, Rodrigo S.
SALUM, Cristiane
Citação
2016 38TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC), p.5262-5265, 2016
Resumo
Prepulse inhibition (PPI) consists of a reduction of the acoustic startle reflex (SR) magnitude (measured with EMG) when a startling stimulus is preceded by a non-startling one. This behavior has been extensively investigated in studies related to schizophrenia, since sensory-motor deficit plays a central role in its pathophysiology. However, the same auditory stimuli that trigger the SR also provoke intense auditory evoked responses (AEP), which can be measured with EEG. Comparing these two types of responses, acquired simultaneously, is a great opportunity to investigate the dependence and interdependence of their neural pathways. Nonetheless, so far very few studies have dared to perform such simultaneous recordings, because SR produces strong eye blinks and muscle contraction artifacts that contaminate EEG electrodes placed on the scalp. In this study we investigated the possibility of simultaneously obtaining both the acoustic SR (using EMG) and the AEP (using EEG) measures, through the use of advanced artifact removal techniques, to better characterize PPI in healthy humans.
Palavras-chave
Pre-pulse inhibition, startle reflex, sensory gating, auditory evoked potentials
Referências
- Brenner CA, 2004, PSYCHOPHYSIOLOGY, V41, P702, DOI 10.1111/j.1469-8986.2004.00206.x
- De Pascalis V, 2013, CLIN NEUROPHYSIOL, V124, P292, DOI 10.1016/j.clinph.2012.07.018
- Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009
- Ford J. M., 1999, STARTLE MODIFICATION, P284, DOI 10.1017/CBO9780511665523.016
- FREEDMAN R, 1991, SCHIZOPHR RES, V4, P233, DOI 10.1016/0920-9964(91)90035-P
- Geyer MA, 2002, MOL PSYCHIATR, V7, P1039, DOI 10.1038/sj.mp.4001159
- Geyer MA, 2001, PSYCHOPHARMACOLOGY, V156, P117, DOI 10.1007/s002130100811
- Graham SJ, 2001, J PSYCHOPHARMACOL, V15, P243
- Hu LL, 2005, I IEEE EMBS C NEUR E, P637
- Kedzior KK, 2006, J PSYCHOPHARMACOL, V20, P471, DOI 10.1177/0269881105057516
- Kedzior KK, 2006, NEUROSCI LETT, V400, P246, DOI 10.1016/j.neulet.2006.02.048
- Makeig S, 2004, TRENDS COGN SCI, V8, P204, DOI 10.1016/j.tics.2004.03.008
- Polich J., 2016, CLIN NEUROPHYSIOL, V118, P2128
- Rentzsch J, 2008, INT J PSYCHOPHYSIOL, V67, P81, DOI 10.1016/j.ijpsycho.2007.10.006